Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Price, News & Analysis

Pear Therapeutics logo

About Pear Therapeutics Stock (NASDAQ:PEAR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
66.30 million shs
Average Volume
7.75 million shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PEAR Stock News Headlines

“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

PEAR Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Pear Therapeutics investors own include Meta Platforms (META), LyondellBasell Industries (LYB), AbCellera Biologics (ABCL), atai Life Sciences (ATAI), CVS Health (CVS), uniQure (QURE) and Absci (ABSI).

Company Calendar

Today
9/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:PEAR
CIK
1835567
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.49 million
Net Margins
-594.70%
Pretax Margin
-594.70%
Return on Equity
-217.85%
Return on Assets
-95.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.48
Quick Ratio
1.48

Sales & Book Value

Annual Sales
$12.69 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
142,739,000
Free Float
98,918,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.45

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:PEAR) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners